Oxford BioDynamics Plc, a British biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, announced that it has entered into an initial collaboration with a major US biopharmaceutical company to advance the discovery and development of novel treatments to address patients with abnormal wound healing response, leading to fibrosis.
Under the terms of the collaboration agreement, the US biopharmaceutical company will be granted access to Oxford Biodynamics unique EpiSwitch™ technology for use in the analysis of structure-function of genome architecture and new insights into fibrotic mechanisms, new targets and new biomarkers.
This will support the development of novel therapeutic candidates and next-generation companion diagnostics, and enable patient population stratification for clinical trials in the area of fibrosis.
Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said: “We are pleased to be collaborating with a major global biopharma company to support the
development of potential novel drug candidates, and the identification of patients suitable for a new fibrosis treatment. This new collaboration is further evidence of broad adoption of our validated proprietary technology EpiSwitch™ for practical use in highly challenging therapeutic development programmes.”